Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Q3 2019 Earnings Conference Call Transcript
Nov 05, 2019 • 04:30 pm ET
Hello and welcome to today's webcast Ligand Pharmaceuticals Third Quarter 2019 Earnings Call. My name is Li Wei and I'll be your event specialist today. [Operator Instructions]
It is now my pleasure to turn today's program over to your SVP of Investor Relations Patrick O'Brien the floor is yours.
Thank you and welcome everybody to Ligand's Third Quarter 2019 Financial results and Business Update Conference Call. Speaking today for Ligand are John Higgins CEO; Matt Foehr COO; and Matt Korenberg CFO. As a reminder, today's call will contain forward-looking statements within the meaning of the federal securities laws. These may include but are not limited to statements regarding intent belief or current expectations of the company and its management regarding its internal and partnered programs. These statements involve risks and uncertainties and actual events or results may differ materially from the projections described in today's press release in this conference call. Additional information concerning risk factors and other matters concerning Ligand can be found in our Ligand's earnings press release and the public periodic filings with the SEC.
The information in this conference call related to projections or other forward-looking statements represents the company's best judgment based on information available and reviewed by the company as of today November 5, 2019, and do not necessarily represent the views of any other party. Ligand undertakes no obligations to revise or update any statements to reflect events or circumstances after the date of this conference call.
At this time I'd like to turn it over to John Higgins.
Welcome to our call. And I'd like to welcome to Ligand and introduce to all of you, Patrick O'Brien. Patrick just joined Ligand yesterday as our Senior Vice President of Investor Relations. Pat welcome.
Thank you, John. It's a pleasure to be here and nice to work with you again.
Yes yes. Absolutely. What -- Since you're on our call Pat how about you share a little bit about your background.
Well really focusing on post-investment banking in the late 1990s started in Investor Relations at Allergan in 2001. And really the bulk of my experience came from my tenure at Gilead which was from 2007 to 2016.
Yes. Fantastic. Well it's great having Patrick on board. His first day was yesterday and if you saw the earnings release his name is now posted in the upper left corner. The business is growing and doing well and as we work with investors a top priority is quality proactive communications with investors. And so we're thrilled to have someone with Patrick's experience running IR for Ligand. I want to acknowledge the outstanding work that Todd Pettingill has done in IR the last two years. I know most of you on the call today have worked closely with Todd and Todd will keep working with Matt Korenberg focusing now entirely on Corporate Development. Todd is in the room here we're going to give him a little pat on the back. Thank you. Really appreciate your excellent work.